Stockscreener 앱 받기
15.99
19.32%
-3.83
시장 영업 전:
16.19
0.20
+1.25%
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
Guggenheim Adjusts Price Target for Beam Therapeutics (BEAM) Amid Ongoing Developments | BEAM Stock News - GuruFocus
Beam Therapeutics price target lowered to $55 from $78 at Guggenheim - TipRanks
Beam Therapeutics (BEAM) Target Price Cut by Wells Fargo Analyst | BEAM Stock News - GuruFocus
Barclays Adjusts Price Target for Beam Therapeutics (BEAM) to $25 | BEAM Stock News - GuruFocus
Beam Therapeutics Reports Strong Q1 2025 Progress - TipRanks
Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus
Why Beam Therapeutics (BEAM) Stock Plummeted Today - GuruFocus
Why Beam Therapeutics Stock Tanked on Tuesday - AOL.com
Why Beam Therapeutics Stock Tanked on Tuesday - The Motley Fool
Why Beam Therapeutics Stock Tanked On Tuesday - Barchart.com
Beam Therapeutics Shares Fall After Q1 Net Loss Widens - marketscreener.com
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Beam (BEAM) Reports Lower-than-Expected Q1 Revenue, Advances Cli - GuruFocus
Beam Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Beam Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$1.24 Mi - GuruFocus
Earnings Flash (BEAM) Beam Therapeutics Posts Q1 License and Collaboration Revenue $7.5M - marketscreener.com
Beam Therapeutics Inc. SEC 10-Q Report - TradingView
Earnings Flash (BEAM) Beam Therapeutics Posts Q1 Loss $1.24, vs. FactSet Est of -$1.18 - marketscreener.com
Beam Therapeutics Inc. Q1 Loss Increases, Misses Estimates - Nasdaq
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - TradingView
Next Generation Genome Editing Market Future Business - openPR.com
(BEAM) Investment Analysis and Advice - news.stocktradersdaily.com
BEAM to Discuss Advances in AATD Therapy at Upcoming Conference Call | BEAM Stock News - GuruFocus
Beam Therapeutics to Report Q1 Earnings: What's in the Cards? - MSN
Cathie Wood’s ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock By Investing.com - Investing.com Nigeria
Cathie Wood’s ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock - Investing.com
Sickle Cell Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Prime Editing and CRISPR Market is Expected to Reach $23.49 - openPR.com
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 29% over the past year - simplywall.st
How To Trade (BEAM) - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? - MSN
Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock - Investing.com
Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal - streetwisereports.com
Share Price Appreciation of Biotech Due Over Next Six Months - streetwisereports.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com India
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease - AOL.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com
Beam Therapeutics Presents Additional Data for BEAM-302 in - GlobeNewswire
Beam Presents Addl. Data From Phase 1/2 Trial Of BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq
Breakthrough: New BEAM-302 Data Shows 91% Success Rate in Rare Liver Disease Treatment - Stock Titan
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' - Benzinga
Beam Therapeutics executive sells $55,330 in stock By Investing.com - Investing.com South Africa
Beam Therapeutics executive sells $55,330 in stock - Investing.com Australia
Beam Therapeutics’ chief legal officer sells $104,121 in stock By Investing.com - Investing.com Canada
Beam Therapeutics’ chief legal officer sells $104,121 in stock - Investing.com India
Beam Therapeutics CEO John Evans sells $562,684 in stock By Investing.com - Investing.com India
5.24%
자본화:
|
볼륨(24시간):